Literature DB >> 10094198

Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion.

C A Benedict1, R Y Tun, D B Rubinstein, T Guillaume, P M Cannon, W F Anderson.   

Abstract

We have attempted to engineer murine leukemia virus (MuLV)-based retroviral vectors to specifically transduce cells expressing human CD34, an antigen present on the surface of undifferentiated hematopoietic stem cells. A number of chimeric ecotropic MuLV envelope (Env) proteins were constructed that contained anti-CD34 single-chain antibody variable fragments (scFvs). The scFv-Env proteins were generated either by replacing the receptor-binding domain of Env with the scFv or by inserting the scFv into the N terminus of the Env protein. Only chimeric Env proteins with scFv insertions between amino acids 6 and 7 were incorporated into viral particles, and coexpression of native MuLV Env did not rescue incorporation-defective proteins. In addition, the efficiency of incorporation varied with the specific anti-CD34 scFv that was used. Retroviral vectors containing the scFv-Env proteins bound to CD34+ cells and transduced NIH 3T3 cells expressing human CD34 (3T3-CD34 cells) at approximately twice the efficiency of the parental NIH 3T3 cells. However, the introduction of the mutation D84K, which prevents binding to the ecotropic MuLV receptor mcat-1, prevented transduction of both NIH 3T3 and 3T3-CD34 cells. Complementation cell-cell fusion assays [Zhao et al. (1997). J. Virol. 71, 6967-6972] in 3T3-CD34 cells revealed that although the scFv-Env proteins could contribute postbinding entry functions when bound to mcat-1, they were unable to do so when bound to CD34. Taken together, these data suggest that although the interaction with CD34 effectively increased the concentration of virus on 3T3-CD34 cells, entry could occur only through an interaction with mcat-1; CD34 alone was not capable of triggering the appropriate postbinding changes that lead to viral entry.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094198     DOI: 10.1089/10430349950018625

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  14 in total

1.  Identification of the block in targeted retroviral-mediated gene transfer.

Authors:  Y Zhao; L Zhu; S Lee; L Li; E Chang; N W Soong; D Douer; W F Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Two point mutations produce infectious retrovirus bearing a green fluorescent protein-SU fusion protein.

Authors:  K Kizhatil; A Gromley; L M Albritton
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor.

Authors:  S Snitkovsky; T M Niederman; B S Carter; R C Mulligan; J A Young
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein.

Authors:  E Bachrach; M Marin; M Pelegrin; G Karavanas; M Piechaczyk
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins.

Authors:  Fang Li; Byoung Y Ryu; Robin L Krueger; Scott A Heldt; Lorraine M Albritton
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

6.  Single-round selection yields a unique retroviral envelope utilizing GPR172A as its host receptor.

Authors:  Peter M Mazari; Daniela Linder-Basso; Anindita Sarangi; Yehchung Chang; Monica J Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-23       Impact factor: 11.205

7.  Receptor binding transforms the surface subunit of the mammalian C-type retrovirus envelope protein from an inhibitor to an activator of fusion.

Authors:  A L Barnett; J M Cunningham
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 8.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

Review 9.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

10.  Directed Molecular Evolution of an Engineered Gammaretroviral Envelope Protein with Dual Receptor Use Shows Stable Maintenance of Both Receptor Specificities.

Authors:  Kristina Pagh Friis; Xavier Iturrioz; Jonas Thomsen; Rodrigo Alvear-Perez; Shervin Bahrami; Catherine Llorens-Cortes; Finn Skou Pedersen
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.